Collaborations

Biopharmaceutical manufacturer collaborates to develop oral vaccination

Published in Cancer Weekly, April 26th, 2005

Cobra Biomanufacturing plc (CBF) announced the results of a 5-year research collaboration with the U.K. Ministry of Defense agency, defense science and technology laboratory (dstl), in Porton Down, U.K., on the development of an improved approach to oral vaccination that avoids the risks of using antibiotics or antibiotic-resistance genes.

Comparison of the ORT-VAC system with conventional bacteria vaccine strains show that, post administration, the ORT VAC product is stable and the conventional strains highly unstable. In other experiments reported in the same paper, using a rigorous plague challenge model in rodents, proof-of-principle results published show that a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-04-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry